Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Eli Lilly’s revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a full portfolio of other products, and some increased revenue in the double ...

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would raise costs and threaten patient access. The drugmaker said last week that the costs for breakthrough medicines ...

Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Eli Lilly shares have soared in the triple digits over the past year. Investors are excited about the company’s prospects in the high-growth, weight-loss drug market. Lilly's recently approved ...

Eli Lilly (NYSE: LLY) stock has soared 90% over the past year, a huge gain for a pharmaceutical company. These stocks generally are known for steady increases over time instead of big movements over a ...

Regardless of your investment style, adding a few pharmaceutical stocks to your portfolio is a great idea. These players offer you a certain amount of stability because, no matter what's happening in ...